[Current Status and Issues of Companion Diagnostics for Non-Small Cell Lung Cancer].

Abstract excerpt

There have been many driver gene abnormalities identified in NSCLC, and the development and clinical adoption of targeting drugs for such are progressing. This has, as a result, complicated the situation surrounding companion diagnostics (CDx). Lung cancer treatment guidelines recommend the use of Multiplex testing that allow for CDx for many driver gene abnormalities to be used prior to 1L treatment for advanced...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antineoplastic Agents
• Share to Biomarkers, Tumor
• Share to Carcinoma, Non-Small-Cell Lung
• Share to Lung Neoplasms
• Share to Molecular Targeted Therapy
• Share to Mutation